Novel EP2 Antagonist Attenuates Microgliosis and Memory Deficits in Pilocarpine-Induced Status Epilepticus Mice
after SE onset in mice attenuated microgliosis in the amygdala, cortex, and hippocampus CA3 region 4 days following recovery from SE. Moreover, memory deficits were prevented in mice at 1-1.5 months following SE. The results validate the notion that neuroinflammation promoted by EP2 exacerbates behavioral deficits, supporting further exploration of EP2 antagonists in the clinical setting.
Authors
- Soheila Pourkhodadad (ORCID: https://orcid.org/0000-0003-1550-0350)
- Raymond J Dingledine (ORCID: https://orcid.org/0000-0001-7128-4520)
- Thota Ganesh (ORCID: https://orcid.org/0000-0002-6163-5590)
- Paola Heman-Bozadas
- R. Jason Herr (ORCID: https://orcid.org/0000-0002-1347-7954)
- Nicholas H. Varvel (ORCID: https://orcid.org/0000-0002-0351-1098)
- Varun Rawat (ORCID: https://orcid.org/0000-0002-3444-4182)
- Qin Jiang (ORCID: https://orcid.org/0000-0003-0541-4635)
- Graham Johnson
Institutions
- Emory University (US)
- Albany Molecular Research (United States) (US)
- Lakeside Labs (AT)
Publication Details
- Journal
- Journal of Medicinal Chemistry
- Published
- 2026-04-15
- DOI
- https://doi.org/10.1021/acs.jmedchem.6c00172
- Primary Topic
- Neuroscience and Neuropharmacology Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- National Institute on Aging
- National Institute of Neurological Disorders and Stroke